These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

292 related items for PubMed ID: 19014887

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. High doses of pergolide improve clinical global impression in advanced Parkinson's disease:- a preliminary open label study.
    Arnold G, Gasser T, Storch A, Lipp A, Kupsch A, Hundemer HP, Schwarz J.
    Arch Gerontol Geriatr; 2005; 41(3):239-53. PubMed ID: 16029905
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A "combined" levodopa test as a useful method for evaluating the efficacy of dopamine agonists: application to pergolide and bromocriptine.
    Bonnet AM, Serre I, Marconi R, Agid Y, Dubois B.
    Mov Disord; 1995 Sep; 10(5):668-71. PubMed ID: 8552122
    [Abstract] [Full Text] [Related]

  • 9. Heart valve regurgitation, pergolide use, and parkinson disease: an observational study and meta-analysis.
    Corvol JC, Anzouan-Kacou JB, Fauveau E, Bonnet AM, Lebrun-Vignes B, Girault C, Agid Y, Lechat P, Isnard R, Lacomblez L.
    Arch Neurol; 2007 Dec; 64(12):1721-6. PubMed ID: 18071034
    [Abstract] [Full Text] [Related]

  • 10. Assessment of valvulopathy in Parkinson's disease patients on pergolide and/or cabergoline.
    Kenangil G, Ozekmekçi S, Koldas L, Sahin T, Erginöz E.
    Clin Neurol Neurosurg; 2007 May; 109(4):350-3. PubMed ID: 17307289
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Trial of subtherapeutic pergolide in de novo Parkinson's disease.
    Grosset K, Grosset D, Lees A, Parkinson's Disease Research Group of the United Kingdom.
    Mov Disord; 2005 Mar; 20(3):363-6. PubMed ID: 15580607
    [Abstract] [Full Text] [Related]

  • 16. Pergolide and Parkinson's disease: new preparation. No clear benefit.
    Prescrire Int; 2000 Dec; 9(50):177-9. PubMed ID: 11475497
    [Abstract] [Full Text] [Related]

  • 17. Valvular heart disease and the use of dopamine agonists for Parkinson's disease.
    Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G.
    N Engl J Med; 2007 Jan 04; 356(1):39-46. PubMed ID: 17202454
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Bromocriptine use and the risk of valvular heart disease.
    Tan LC, Ng KK, Au WL, Lee RK, Chan YH, Tan NC.
    Mov Disord; 2009 Feb 15; 24(3):344-9. PubMed ID: 18989898
    [Abstract] [Full Text] [Related]

  • 20. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease.
    Van Camp G, Flamez A, Cosyns B, Weytjens C, Muyldermans L, Van Zandijcke M, De Sutter J, Santens P, Decoodt P, Moerman C, Schoors D.
    Lancet; 2004 Apr 10; 363(9416):1179-83. PubMed ID: 15081648
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.